Intravesical Instillations with Bacillus Calmette-Guérin for the Treatment of Carcinoma In Situ Involving Prostatic Ducts

European Urology

Volumn 49, Issue 5, 2006, Pages 834-838

  Palou Redorta, Juan ^a   Schatteman, Peter ^a   Huguet Pérez, Jorge ^a   Segarra Tomás, Joséph ^a   Rosales Bordes, Antonio ^a   Algaba, Ferran ^a   Villavicencio Mavrich, Humberto ^a  

^a FUNDACIÓ PUIGVERT   (Spain)

Author keywords

BCG; Prostatic duct; Urothelial cell carcinoma

Indexed keywords

BCG VACCINE; CISPLATIN; DOXORUBICIN; METHOTREXATE; MITOMYCIN; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER NECK; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; CAUSE OF DEATH; CLINICAL ARTICLE; CYSTECTOMY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MALE; METASTASIS; MUSCLE TUMOR; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; SOLID TUMOR; STROMA; TRANSURETHRAL RESECTION; URETHRA CANCER; UROGENITAL TRACT CANCER;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; BIOPSY; CARCINOMA IN SITU; CYSTECTOMY; CYSTOSCOPY; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; INSTILLATION, DRUG; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; URETHRAL NEOPLASMS;

EID: 33645753074     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.019     Document Type: Article

References (21)

1. Soloway M.S., Sofer M., and Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167 (2002) 1573
2. Hillyard R.W., Ladaga L., and Schellhammer P.F. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guérin. J Urol 139 (1998) 290
3. Hardeman S.W., and Soloway M.S. Transitional cell carcinoma of the prostate: diagnosis, staging and management. World J Urol 6 (1988) 170-174
4. Wishnow K.I., and Ro J.Y. Importance of early treatment of transitional cell carcinoma of prostatic ducts. Urology 32 (1988) 11-12
5. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180
6. Schellhammer P.F., Ladaga L.E., and Moriarty R.P. Intravesical bacillus Calmette-Guérin for treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J Urol 153 (1995) 53
7. Schellhammer P.F., Bean M.A., and Whitmore W.F. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol 118 (1977) 399-403
8. Chibber P.J., McIntyre M.A., Hindmarsh J.R., Hargreave T.B., Newsam J.E., and Chisholm G.D. Transitional cell carcinoma involving the prostate. Br J Urol 53 (1981) 605-609
9. Palou J., Xavier B., Laguna P., Motlleo M., and Vicente J. In situ transitional cell carcinoma involvement of the prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate. Urology 47 (1996) 482
10. Bretton P.R., Herr H.W., Whitmore W.F., et al. Intravesical bacillus Calmette-Guérin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 141 (1989) 853-855
11. Canda A.E., Tuzel E., Mungan M.U., Yorukoglu K., and Kirkali Z. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of bladder. Eur Urol 45 (2004) 465-470
12. Hardeman S.W., Perry A., and Soloway M.S. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder. J Urol 140 (1988) 289-292
13. Van der Meijden A., Oosterlinck W., Brausi M., Kurth K.H., Sylvester R., and de Balincourt C. Significance of bladder biopsies in Ta T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Cancer. Eur Urol 35 (1999) 267-271
14. Sakamoto N., Tsuneyoshi M., Naito S., and Kumazawa J. An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients. J Urol 149 (1993) 318-321
15. Wood D.P., Montie J.E., Edson Pontes J., and Levin H.S. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study. J Urol 142 (1989) 83-85
16. Honda N., Yamada Y., Okada M., et al. Clinical study of transitional cell carcinoma of the prostate associated with bladder transitional cell carcinoma. Int J Urol 8 (2001) 662-668
17. Lamm D., Stogdill V.D., Stogdill B.J., and Crispen R. Complications of bacillus Calmette-Guérin immunotherapy in 1278 patients with bladder cancer. J Urol 135 (1986) 272-274
18. Lamm D.L. Editorial comment. J Urol 141 (1989) 855
19. Reese H.J., Freiha F.S., Gelb A.B., Lum B.L., and Torti F. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol 147 (1992) 92-95
20. Wittekind C.h., Henson D.E., Hutter R.V.P., and Sobin L.H. TNM Supplement. A commentary on uniform use. 2nd ed. (2001), Wiley-Liss, John Wiley and Sons, New York
21. Huguet J., Crego M., Sabaté S., Salvador J., Palou J., and Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48 (2005) 53-59